The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > ORGANIZATION
ORGANIZATION
- Kenporen Director Kono: Apply CEA to Reimbursement Decisions Once Credible System Established
March 18, 2019
- Drug Damage Watchdog Opposes Legislation of Conditional Approval System, Calls for Tougher Rules on Ads
March 13, 2019
- Look at Societal Values of Medicines in Pricing: Japan Pharma Industry Chief
March 12, 2019
- Japan Has High Market Access Barriers, Revised PMP Could Stymie Innovation: US Chamber of Commerce Official
March 7, 2019
- Biotech Execs Raise Alarm over Price Maintenance Criteria, CEA Introduction: BIO Asia Confab
March 6, 2019
- Labor Groups Call for Careful Discussions on Cost Effectiveness Assessment
February 19, 2019
- EFPIA Japan Chief Says CEA Selection Criteria Mar Predictability, 5 Billion Yen Sales Threshold “Too Low”
February 19, 2019
- 2019 Is Year to “Get Things Right”: PhRMA Japan Chairman
February 8, 2019
- Sanofi CEO Becomes Chairman of PhRMA
February 6, 2019
- PhRMA Takes Issue with Japan Govt’s Overreliance on ICER, Proposes Point-Based Appraisal Framework
February 5, 2019
- JPMA Lays Out Policy Proposal 2019, Advocates Pricing Premium for Drugs Used for Pregnant Women
January 25, 2019
- Think Tank Urges Govt to Look at Drugs with Large Prescription Volumes Too
January 25, 2019
- Regional Formulary Initiatives Underway, Eyes on Cost Control for Branded Drugs with No Gx
January 22, 2019
- Don’t Cause Disruptions in Drug Distribution with October Re-Pricing: Japan Wholesaler Chief
January 15, 2019
- Budget Juggling Dependent on Drug Price Cuts Unacceptable: Tokyo Pharma Chief
January 9, 2019
- Generic Use Rate at 73.2% in July-September: JGA
December 27, 2018
- JMA Chief Pushes September 2019 Drug Price Announcement for Ad-Hoc Revision
December 27, 2018
- Use of Generics and Formulary Would Reduce Drug Expenditure by 38%: Payer Estimate
December 27, 2018
- March Announcement of NHI Price List “Not an Option”, Says Wholesaler Group
December 25, 2018
- October 2019 Drug Price Revision a Relief for JPMA: Official
December 25, 2018
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…